throbber
Free Radical Biology & Medicine, Vol. 37, No. 8, pp. 1122–1143, 2004
`Copyright D 2004 Elsevier Inc.
`Printed in the USA. All rights reserved
`0891-5849/$-see front matter
`
`doi:10.1016/j.freeradbiomed.2004.06.013
`
`Serial Review: Mechanisms and Novel Directions in the Biological Applications
`of Nitric Oxide Donors
`Serial Review Editor: S. Bruce King
`
`NITRATES AND NO RELEASE: CONTEMPORARY ASPECTS IN
`BIOLOGICAL AND MEDICINAL CHEMISTRY
`
`GREGORY R. J. THATCHER, ADRIAN C. NICOLESCU,
`
`1 BRIAN M. BENNETT,
`
`1
`
`and VIOLETA TOADER
`
`Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy,
`University of Illinois at Chicago, 833 S. Wood Street, Chicago, IL 60612-7231, USA
`
`(Received 10 May 2004; Accepted 3 June 2004)
`Available online 6 July 2004
`
`Abstract—Nitroglycerine has been used clinically in the treatment of angina for 130 years, yet important details on the
`mechanism of action, biotransformation, and the associated phenomenon of nitrate tolerance remain unanswered. The
`biological activity of organic nitrates can be said to be nitric oxide mimetic, leading to recent, exciting progress in
`realizing the therapeutic potential of nitrates. Unequivocally, nitroglycerine and most other organic nitrates, including
`NO-NSAIDs, do not behave as NO donors in the most fundamental action: in vitro activation of sGC to produce cGMP.
`The question as to whether the biological activity of nitrates results primarily or exclusively from NO donation will not
`be satisfactorily answered until the location, the apparatus, and the mechanism of reduction of nitrates to NO are defined.
`Similarly, the therapeutic potential of nitrates will not be unlocked until this knowledge is attained. Aspects of the
`therapeutic and biological activity of nitrates are reviewed in the context of the chemistry of nitrates and the elusive
`
`reduction required to generate NO. D 2004 Elsevier Inc. All rights reserved.
`efficient 3e
`
`Keywords—Nitrate, Nitric oxide, Biotransformation, cGMP, Signaling, Nitration, Nitrosation, Free radicals
`
`Contents
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`Introduction .
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`Nitrates as therapeutic agents .
`.
`.
`.
`.
`.
`.
`Nitrate biotransformation and tolerance .
`.
`.
`.
`.
`.
`.
`Nitrates as nitric oxide donors.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`Nitrates, NO, and sGC activation .
`.
`.
`.
`NO release from nitrates: models and mechanisms .
`Reactions of nitrates with thiols .
`.
`.
`.
`.
`.
`.
`.
`.
`Thionitrates and sulfenyl nitrites .
`.
`.
`.
`.
`.
`.
`.
`.
`Reactions of nitrates with metal ion assistance .
`Conclusions .
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`Acknowledgment
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`References .
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`.
`
`1123
`1124
`1127
`1128
`1129
`1131
`1132
`1133
`1134
`1135
`1135
`1135
`
`This article is part of a series of reviews on bMechanisms and Novel Directions in the Biological Applications of Nitric Oxide Donors.Q The full list
`of papers may be found on the home page of the journal.
`Address correspondence to: Greg Thatcher, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at
`Chicago, 833 S. Wood St., Chicago, IL 60612-t7231, USA; Fax: (312) 996 7107; E-mail: thatcher@uic.edu.
`1
`Present address: Department of Pharmacology & Toxicology, Queen’s University, Kingston K7L 3N6, Canada.
`
`1122
`
`Human Power of N Company
`EX1048
`Page 1 of 22
`
`

`

`Nitrates and NO release
`
`1123
`
`INTRODUCTION
`
`The organic nitrate nitroglycerine is well into its second
`century of use both as a medicinal agent and as an agent
`of destruction and suffering. In popular culture nitro-
`glycerine is used as a simile for anything that is volatile
`and explosive under the merest provocation. A search of
`the Web will generate equal mentions of the use of
`nitroglycerine in terrorist and sniper attacks and in new
`therapeutic applications from spider bites,
`to anal
`fissures,
`to restless leg syndrome. Despite its deep
`history, knowledge of the biological chemistry of nitro-
`glycerine and of nitrates in general is wholly incomplete.
`The synthesis of nitroglycerine was first reported in
`1846, and 20 years later, the taming of nitroglycerine in
`the form of dynamite and gun glycerine was the basis of
`Alfred Nobel’s fortune. Nobel’s contemporaries, Thomas
`Brunton, who was studying the effects of organic nitrites
`in angina pectoris, and William Murrell, who demon-
`strated that small doses of nitroglycerine taken sublin-
`gually provided rapid and remarkable relief from the
`intense pain of angina, are generally credited with the
`development of nitroglycerine as a therapeutic agent
`[1,2]. Nitroglycerine was renamed glyceryl
`trinitrate
`(GTN), to avoid the anxiety associated with ingesting a
`high explosive, and has been used continuously in
`treatment of angina since 1878. GTN has also been
`applied in controlled hypotension during cardiac surgery
`and in congestive heart
`failure. Decreased cardiac
`preload due to the selective venodilator response to
`organic nitrate vasodilators is the basis for their clinical
`use in treatment of angina;
`these, and other simple
`nitrates that have been used only as biological probes, we
`may class as bclassical nitratesQ (Fig. 1).
`Sinitrodil, FR 46171, and nicorandil represent nitrates
`containing functionalities, other than simple hydrocarbon
`or sugar skeletons, which influence biological activity
`(Fig. 1). Sinitrodil is proposed as an agent with enhanced
`antianginal and attenuated hypotensive activity relative
`to classical nitrates due to reduced dilation of the smaller
`coronary and resistance vessels and the resultant effects
`
`on mean arterial blood pressure and heart rate [3,4].
`Nicorandil
`is a nitrovasodilator that
`is also a KATP
`channel opener, which is in preclinical and clinical
`studies for vascular diseases,
`including myocardial
`infarction [5,6]. Nitrate esters have a significant clinical
`attribute in that a nitrate is, inherently, considerably more
`lipophilic than its parent alcohol, allowing delivery by
`routes including sublingual or transdermal, as used in
`slow-release GTN patches. Oral administration of GTN
`is ineffective because of rapid first-pass metabolism, but
`the lone criticism of GTN as a therapeutic agent is the
`onset of clinical nitrate tolerance during chronic admin-
`istration. The physiological perturbation that causes
`tolerance is not known, but most theories have a central
`role for attenuated nitrate bioactivation (also termed
`mechanism-based biotransformation). The efficient bio-
`transformation of nitrates is also central to the therapeutic
`activity of nitrate drugs, because it is almost universally
`assumed that nitrates are in fact NO prodrugs, although
`the details of this mechanism-based biotransformation of
`the nitrate moiety (RONO2) to NO remain uncertain.
`The pharmaceutical development of nitrates contain-
`ing adjunct pharmacophores is not a new pursuit. For
`example, steroid nitrates had been reported over 40 years
`ago and observed to manifest biological properties
`beyond those of the parent steroid [7,8]. However, there
`has been an explosion of activity in the area of hybrid
`nitrates over the past decade stimulated by the actions of
`Del Soldato and NicOx SA (France) in developing NO-
`NSAIDs (NO-donating nonsteroidal anti-inflammatory
`drugs), sometimes known as CINODs (cyclooxygenase
`inhibitory NO donors), and in promoting the scientific
`study of these compounds (Fig. 2) [9–12]. Interest in the
`further use of nitrates in new cardiovascular applications
`is increasing, but
`there is a growing realization that
`nitrates may represent new therapeutic agents in non-
`traditional areas, for example, in neuroprotection and
`neuropathic pain [13–17]. This represents a paradigm
`shift that has been inspired by discoveries in NO biology
`and pharmacology, examples being the application of
`nitrates in dementia [13], the association of nitrates and
`
`Fig. 1. Nitrate vasodilators, including classical nitrates: erithrityl tetranitrate (ETN), glyceryl trinitrate (GTN), pentaerithrityl tetranitrate
`(PETN), isosorbide dinitrate (ISDN), isosorbide-5-mononitrate (5ISMN).
`
`Page 2 of 22
`
`

`

`1124
`
`G. R. J. Thatcher et al.
`
`Fig. 2. Selected NO-NSAIDs and hybrid nitrates. These nitrates are all described as NO-donor drugs and are in preclinical or clinical
`trials for a range of indications; NO-naproxen, AZD 3582, has completed Phase 2 clinical trials.
`
`NO with regulation of glutamate receptors [18–20], and
`the proposal of hybrid nitrate drugs containing the
`noncompetitive, open-channel NMDA receptor antago-
`nist memantine [21]. There are two observations that are
`common to many of the published studies on NO-
`NSAIDs and hybrid nitrates: (i) the biological activity of
`the nitrate is greater than that of the parent and (ii) the
`biological activity observed is not seen for the parent
`pharmacophore [22]. A further common observation is
`that neither the chemical mechanism nor the biological
`apparatus for release of NO is understood.
`Nitrate esters or organic nitrates contain the nitrooxy
`functional group (ONO2), almost all examples being
`aliphatic nitrates, owing to the presumed instability of the
`aromatic nitrate to rearrangement [23]. Contrary to some
`descriptions, nitrates are not nitroso compounds. This is
`not a point of semantics, because nitroso compounds,
`U
`NjO), nitrosamines
`including nitrosothiols (RS
`U
`U
`NjO), and nitrosoalkanes (RRVRVC
`NjO)
`(RRVN
`require only one electron reduction to yield NO.
`Conversion of the nitrooxy group of nitrates to NO is a
`three-electron reduction that must involve oxygen atom
`transfer. To date, no purified protein system has been
`demonstrated to mediate the direct reduction of nitrates
`to yield relevant quantities of NO, although it is widely
`held that the biologically active product of mechanism-
`based biotransformation of nitrates is NO [24,25]. The
`present article reviews the potential chemical mecha-
`nisms and the biochemical pathways associated with
`nitrate biotransformation. There is a vast literature on the
`biological activity of various nitrates, in contrast to a
`relative paucity of studies on the biological chemistry.
`Endogenous nitrates may be formed in vivo, for example
`in lipid peroxidation radical chain termination by nitric
`
`oxide [26–28], but nitrates are first and foremost
`exogenous therapeutic agents and it
`is the biological
`chemistry of these compounds that is of primary interest.
`
`NITRATES AS THERAPEUTIC AGENTS
`
`Physiologically, NO is produced enzymatically from
`the terminal guanidino nitrogen of l-arginine, by nitric
`oxide synthase (NOS). Endothelial NOS (eNOS) releases
`NO, which causes inhibition of platelet aggregation and
`vasodilation via activation of soluble guanylyl cyclase
`(sGC)
`in underlying vascular smooth muscle cells.
`Inducible NOS is found in many tissues and, in macro-
`phages, when induced, produces NO as part of the body’s
`immune response. NO from neuronal NOS is involved in
`neurotransmission in the central nervous system. These
`are only some of the multitude of biological roles for NO,
`which have been amply reviewed elsewhere [29–36].
`Because nitrates seem in many respects to act as
`exogenous NO sources,
`this would suggest a large
`number of potential
`therapeutic applications. Circum-
`venting nitrate tolerance in current cardiovascular thera-
`pies would be beneficial, but the newer applications of
`nitrates outside of angina and cardiovascular indications
`hold the most exciting promise. A review of the novel
`nitrate therapies under development is beyond the scope
`of
`this article, but
`it
`is worthwhile examining the
`biotransformation of nitrate therapeutics, because if
`nitrates are indeed NO-donor drugs,
`these metabolic
`pathways must involve the chemical generation of the
`NO free radical.
`In addition to GTN, several classical nitrates, and
`nicorandil, the most extensive published data on nitrate
`metabolism is for the NO-NSAIDs and related hybrid
`
`Page 3 of 22
`
`

`

`Nitrates and NO release
`
`1125
`
`
`on
`was reported to release increased amounts of NO2
`addition of esterase [38]. Unfortunately,
`the frequent
`
`as a measure of NO
`reporting of the Griess test for NO2
`release obfuscates the analysis and understanding of the
`mechanisms of action and of biotransformation, and this,
`in part, has led to some confusion in the literature as to
`the metabolic pathway that leads to NO release from
`these nitrates, with several claims that NO release simply
`requires the action of an esterase (e.g. [37]).
`The action of an esterase or nonenzymatic hydrolysis
`in the gut does not release NO, but generates a simple
`aliphatic nitrate, in the case of NCX 4016, hydroxyben-
`zyl nitrate (HBN), or, in the cases of NCX 4215 and
`AZD 3582, hydroxybutyl nitrate (Fig. 4). Therefore,
`focusing on the NO-ASA NCX 4016, one must query
`why a combination therapeutic of ASA and a benzyl
`nitrate does not provide similar benefits and even a
`clinical advantage in the ability to titrate the NO and
`NSAID effects independently (Fig. 4). In reviewing NO-
`NSAIDs in colon cancer chemoprevention, Rigas poses
`the same question of the effectiveness of classical nitrates
`in combination with NSAIDs in such indications [39,40].
`Ester hydrolysis of the NO-NSAID yields a primary
`aliphatic nitrate which may undergo subsequent reduc-
`
`) or nucleo-
`tive denitration to inorganic nitrite (NO2
`
`philic substitution to generate inorganic nitrate (NO3
`)
`(Fig. 4). There is ample evidence that a number of
`
`Fig. 3. General depiction of the mode of NO release from NO-NSAIDs
`and other hybrid nitrates.
`
`nitrates (Fig. 2). The latter two classes of agents are
`explicitly described in the literature as NO-donor drugs,
`but it must be emphasized that these compounds do not
`merely bresemble organic nitrates,Q they are nitrates and
`will manifest nitrate chemistry. NO-NSAIDs and related
`hybrid nitrates are proprodrugs, containing an ester
`moiety that is cleaved by nonspecific esterase action:
`the general depiction of such NO-donor drugs (using an
`NO-NSAID as an example in Fig. 3) is of an NO moiety
`(more accurately a nitrate moiety) connected via a linker
`to the parent pharmacophore. It
`is reported that
`the
`activity of NO-NSAIDs and hybrid nitrates in vitro is
`influenced by addition of esterases, for example, NCX
`1015 at high micromolar concentrations (100–500 AM)
`
`
`
`
`
`Fig. 4. (1) Biotransformation of an NO-NSAID therapeutic leading to eventual formation of inorganic nitrate, inorganic nitrite, and NO.
`A large number of enzymes, including cytochrome P450 oxidase, cytochrome P450 reductase, glutathione S-transferase, and aldehyde
`
`. Nucleophiles such as glutathione (GSH)
`dehydrogenase, have been demonstrated to mediate the reductive denitration of nitrates to NO2
`may displace inorganic nitrate via SN2 substitution. This analysis suggests that (2) a combination therapy might have similar
`effectiveness. (3) Hybrid nitrates, similarly, are designed to hydrolytically yield free thiol and simple aliphatic nitrate.
`
`Page 4 of 22
`
`

`

`1126
`
`G. R. J. Thatcher et al.
`
`
`
`reduction of
`diverse enzymes may catalyze the 2e
`
`
`nitrates to NO2
`is a good
`(vide infra), whereas NO3
`leaving group for nucleophilic substitution. In contrast,
`there is no unambiguous evidence for any enzyme
`
`reduction of nitrates to NO.
`catalyzing the direct 3e
`There is little evidence for significant biological activity
`
`,
`the levels of which in human
`associated with NO3
`plasma and rat aorta are relatively high (~25 and ~50
`AM) and fluctuate substantially with diet
`[41–43].
`However,
`there is renewed interest
`in the biological
`
`, which has been shown to be oxidized
`activity of NO2
`by peroxidase to NO2 [44,45] and to be reduced by
`ferrous hemoglobin (Hb) to yield NO-Hb or NO [43].
`
`have been
`Physiological concentrations of NO2
`reported to range from 0.5 to 25 AM in plasma and
`tissue and may be higher under pathophysiological
`
`has
`conditions [46,47]. The direct addition of NO2
`failed to elicit a biological response in several systems
`[41,48,49]; however, compartmentalization and active
`transport, combined with the demonstrated reactivity of
`
`with transition metal centers,
`leaves open a
`NO2
`
`, via its oxidation or
`its
`biological
`role for NO2
`reduction products [43,50–52]. Thus, it is possible that
`
`-donor drugs,
`nitrates act, not as NO donors, but as NO2
`
`to specific
`providing intracellular delivery of NO2
`locations.
`The metabolism of the NO-NSAID NCX 4016, has
`been studied in detail [53–57]. In rats, the intact nitrate,
`NCX 4016, was not detected in plasma after oral
`administration, and in rat liver microsomal S9 fractions,
`metabolism was complete within 5 min. The sole
`observable nitrate in rat liver fractions was HBN and
`the glutathione adduct shown in Fig. 4. Compatible with
`these observations, after administration in rats, plasma
`
`levels were unchanged (~1 AM), whereas plasma
`NO2
`
`was elevated from ~20 to ~130 AM over 6 h.
`NO3
`Reports of detection of NO itself as a product of in vivo
`administration of NO-NSAIDs are limited: NO-Hb was
`observed in rat blood and NO-Mb (myoglobin) in
`myocardial tissue in vivo and in vitro after administration
`of NCX 4016, using the sensitive ESR spectroscopic
`detection technique. Using this method, ISMN and NCX
`4016 (1 mM) generated similar levels of NO-Hb (~30 AM
`at 1 h) in rat blood. Because ferrous-Hb is known to react
`
`to generate NO-
`directly with nitrates, nitrites, and NO2
`Hb, it is difficult conclude from these experiments that the
`NO-NSAID nitrates are directly reductively biotrans-
`formed to NO in vivo. Thus, the best studied NO-NSAID,
`NCX 4016, is claimed to be largely absorbed in the small
`intestine, subject to substantial first-pass metabolism, and
`to possess little or no systemic bioavailability. Exciting
`data on the CNS activity of the NO-flurbiprofen NO-
`NSAIDs have been assembled [15,58], and like NCX
`4016, the nitrooxybutyloxy ester of flurbiprofen under-
`
`goes rapid, extensive first-pass metabolism in rats, such
`that: (i) only flurbiprofen could be detected in brain and
`
`+
`plasma in significant amounts and (ii) levels of (NO2
`
`) increased in plasma over 8 h, but were unchanged
`NO3
`in brain [59]. The hydroxybutyl nitrate metabolite was not
`quantified in this study.
`The wealth of exciting biological data being generated
`on NO-NSAIDs and on hybrid nitrates demonstrates
`enhanced and additional biological activity over the
`parent pharmacophores, which would be very difficult
`to explain simply by enhanced bioavailability deriving
`from either the increased lipophilicity of the nitrate
`derivative or the increased local blood flow due to nitrate
`vasodilation. The published data show that NO-NSAIDs
`are rapidly metabolized to simple aliphatic nitrates, and in
`
`.
`the case of NCX 4016, the major NOx metabolite is NO3
`Classical nitrates are themselves simple aliphatic nitrates:
`GTN is rapidly metabolized to yield further simple
`
`. Therefore, metab-
`aliphatic nitrate metabolites and NO2
`olism studies confirm that nitrates, whether classical or
`
`
`.
`and NO3
`modernist, are efficiently metabolized to NO2
`In contemporary nitrate therapeutics, hybrid nitrates in
`which the nitrooxy group is ancillary to a primary
`pharmacophore have generated the majority of reports;
`however, Schwarz Pharma scientists were the first to
`describe hybrid nitrates that contain a cysteine moiety,
`designed to be metabolized to free cysteine and a free,
`simple aliphatic nitrate (Fig. 4) [60,61]. This design is
`based upon the postulates either that free thiol is needed
`for biotransformation of nitrates or that thiol overcomes
`nitrate tolerance. A natural extension of this design is a
`hybrid nitrate which will release a free thiol other than
`cysteine, for example thiosalicylic acid (TSA), which
`like cysteine is an bactive thiolQ toward nitrates (vide
`infra) (Fig. 4) [62,63].
`Hybrid nitrates are uniformly designed to metabol-
`ically degrade to yield a simple aliphatic nitrate (and
`thence NO), and observations show that much of the
`therapeutically beneficial biological activity derives from
`the aliphatic nitrate moiety of such drugs. It is therefore
`reasonable to explore the structure–activity relationships
`of aliphatic nitrates themselves toward NO mimetic
`biological activity and toward metabolism or degradation
`to NO, by design of novel nitrates through incorporation
`of other
`functional groups into the organic nitrate
`[26,64,65]. These nitrates are predicted to show a
`different spectrum of NO mimetic activity to simple or
`classical nitrates, which has been borne out in literature
`reports. The disulfanyl S-nitrate GT 715 has been
`reported: (a) to reduce the cerebral infarct in the rat
`middle cerebral artery occlusion model of ischemic
`stroke by 60–70% when delivered 4 h after the onset
`of ischemia [66] and (b) to reverse the scopolamine-
`induced cognitive deficit in the Morris water task rat
`
`Page 5 of 22
`
`

`

`Nitrates and NO release
`
`1127
`
`behavioral model of dementia [13]. Interestingly, these
`studies showed that the S-nitrate was more effective and
`relatively more potent than GTN in activating hippo-
`campal sGC and demonstrated greatly attenuated periph-
`eral vasodilatory responses compared to GTN. A
`member of the S-nitrate family is currently in clinical
`trials for Alzheimer’s disease.
`
`NITRATE BIOTRANSFORMATION AND TOLERANCE
`
`Mechanism-based biotransformation of nitrates has
`been defined as the pathway generating a proximal
`activator of sGC in vascular smooth muscle cells, which
`is presumed to be NO, whereas the term clearance-based
`biotransformation has been coined to describe pathways
`that lead to nitrate metabolism without activation of sGC,
` [67,68]. The biotransfor-
`often presumed to be via NO2
`mation of GTN yields the dinitrate metabolites glyceryl-
`1,2-dinitrate (1,2-GDN) and glyceryl-1,3-dinitrate (1,3-
`GDN) as products. The vascular biotransformation of
`GTN is regioselective for formation of 1,2-GDN [69–
`74], and it is this isomer that is formed exclusively during
`the initial exposure of tissues to GTN [75]. In tolerant
`cultured cells and tissues, the regioselectivity is lost and
`GTN biotransformation is attenuated [76–79]. Several
`proteins have been identified that are capable of
`mediating the denitration of GTN, yielding GDN and
` as products, including Hb, Mb, xanthine oxidor-
`NO2
`eductase (XOR), old yellow enzyme, glutathione S-
`transferase (GST), cytochrome P450 oxidase (CYP), and
`cytochrome P450 reductase [73,74,78,80–87]. More
`recently, it was confirmed that ALDH2 was capable of
`mediating denitration of classical nitrates [88–90].
`Long-term administration of nitrates is characterized
`by a decrease in their vasodilator and antianginal
`effectiveness, which is termed nitrate tolerance. Clinical
`tolerance can be simulated in animal models by
`continuous delivery of GTN, but not by repetitive bolus
`administration [91]. There have been proposed two major
`hypotheses for nitrate tolerance: blood vessel-dependent
`and vessel-independent mechanisms. The blood vessel-
`dependent hypothesis accounts for
`the inability of
`vascular smooth muscle cells to adequately respond to
`nitrates, whereas the vessel-independent hypothesis
`accounts for the activation of neurohormonal counter-
`regulatory mechanisms (e.g.,
`intravascular volume
`expansion, increase in catecholamine levels, and activa-
`tion of the renin–angiotensin system) [92]. A major
`criticism of the involvement of neurohormonal mecha-
`nisms is that tolerance can be induced in isolated vessels
`in which the presence of circulating vasoconstrictor
`hormones is excluded, although the possibility exists
`that
`in vitro tolerance models do not reflect clinical
`nitrate tolerance [93].
`
`S
`
`S
`
`S
`
`tolerance mecha-
`Several blood vessel-dependent
`nisms have been suggested: (i) attenuation of nitrate
`bioactivation [67,68,94,95],
`(ii) generation of
`free
`radicals during nitrate biotransformation [69,92,95–97],
`(iii) upregulation of phosphodiesterase activity with the
`subsequent reduction in intracellular levels of cGMP
`[98], (iv) loss of sGC responsiveness to NO [99–101],
`and (v)
`intracellular depletion of
`thiol equivalents
`[102,103]. The observation that spontaneous NO donors
`(e.g., nitroprusside, nitrosothiols, and diazeniumdiolates)
`are not subject to tolerance or to cross-tolerance toward
`nitrates has been argued to support
`the attenuated
`mechanism-based biotransformation of nitrates in toler-
`ant vessels as the mechanism underlying tolerance. The
`thiol depletion hypothesis of Needleman and Johnson
`proposed that tolerance might result from depletion of
`critical thiols which are involved in the metabolism of
`nitrates [102]. However, a causal role in clinical nitrate
`tolerance due to reduced bioavailability of sulfhydryl
`groups was not confirmed by more recent investigations
`[104,105].
`A proposed free radical hypothesis of nitrate toler-
`ance is based on the observation that administration of
`,
`GTN increases the endothelial production of O2
`although this observation does not seem to hold for
`can
`nitrates in general [72,106]. The elevation of O2
`limit
`the bioavailability of both endogenous and
`exogenous NO through the near diffusion-controlled
`with NO yielding peroxynitrite
`reaction of O2
`
`), which has been reported to be formed during
`(ONOO
`the uninterrupted administration of nitrates in both
`animals and humans [95,106,107]. Peroxynitrite is an
`oxidizing and nitrating cytotoxin that has been assigned
`roles in nitrate tolerance through interference with the
`normal function of NOS and cGMP-dependent protein
`kinase I [94,95].
`The loss of regioselectivity for GTN denitration in
`tolerant tissue is dramatic and might be taken to suggest
`that the mechanism-based biotransformation pathway is
`regioselective. However, it is quite reasonable to expect
`clearance-based metabolism also to show regioselectivity
`and for both pathways to be attenuated in tolerant tissue.
`For example, the selective flavoprotein inhibitor diphe-
`nyleneiodonium sulfate (DPI) was shown to attenuate the
`regioselectivity for formation of 1,2-GDN,
`to inhibit
`cGMP accumulation in blood vessels, and not to inhibit
`tissue relaxation induced by spontaneous NO donors, but
`DPI inhibited GTN-induced relaxation to the same extent
`in aortae from naRve and from GTN-tolerant animals
`[71,78]. These observations force the conclusion that
`flavoproteins are important for nitrate metabolism and
`may participate in biotransformation leading to vaso-
`dilation, but their alteration cannot be the basis for nitrate
`tolerance. Regioselectivity is not therefore, by itself, a
`
`Page 6 of 22
`
`

`

`1128
`
`G. R. J. Thatcher et al.
`
`sufficient criterion for identification of mechanism-based
`biotransformation. ALDH2 activity in hepatic mitochon-
`dria also shows significant regioselectivity toward 1,2-
`GDN formation from GTN, which is lost in mitochondria
`from tolerant tissue [88,108]. Owing to the perceived
`importance of ALDH2 in GTN metabolism, the data on
`ALDH2 need further discussion [109].
`In rabbit aorta in which in vitro tolerance was induced
`by soaking of tissues in high GTN concentration, ALDH
`activity was reduced, and in addition, compounds that
`inhibit ALDH activity (cyanamide, aldehydes and their
`hydrates, at 1 mM) inhibited GTN biotransformation,
`relaxation, and GTN-induced cGMP accumulation in
`isolated blood vessels [88]. One might reasonably take
`these data to suggest a role for ALDH2 in nitrate
`bioactivation. In vivo studies are confounded because the
`inhibitors currently used are metabolically and redox
`labile (including aldehydes/hydrates;
`isoflavones, e.g.,
`daidzein; and thiocarbamate inhibitors, e.g., disulfiram,
`benomyl): many require biotransformation themselves
`and are not specific for ALDH2, having been shown to
`inhibit other sulfhydryl-dependent enzymes and metal-
`loenzymes including CYPs [110–115]. The lack of
`specificity of enzyme inhibitors has been commented
`on as a general problem, not
`limited to studies on
`ALDH2, in the identification of the enzyme responsible
`for nitrate biotransformation and tolerance [68].
`Continuous delivery of GTN via a transdermal patch
`in rats provides an in vivo model of clinical nitrate
`tolerance, validated by the markedly reduced blood
`pressure response to GTN observed in the intact animal
`[116]. Both propionaldehyde and cyanamide attenuated
`the regioselectivity of GTN biotransformation in hepatic
`mitochondria, and both compounds inhibited tissue
`relaxation induced by GTN in naRve aortae; importantly,
`however, both compounds also inhibited relaxation in
`tolerant aortae to the same extent as in naRve aortae (Fig.
`5) [108]. These and other data are compatible with a role
`for ALDH2 in mechanism- and clearance-based nitrate
`biotransformation, but are incompatible with a dominant
`role for ALDH2 in nitrate tolerance [108]. The actions of
`cyanamide and aldehydes on blood pressure and tissue
`relaxation were taken to reflect a nonspecific inhibitory
`action on GTN-induced relaxation. Furthermore,
`the
`numerous biochemical pathways that potentially contrib-
`ute to nitrate tolerance would suggest that this is likely a
`multifactorial phenomenon, which includes attenuation
`of one or more mechanism-based biotransformation
`pathways.
`The concentration–response curves shown in Fig. 5
`represent
`typical data on the effect of in vivo GTN
`tolerance on GTN-induced tissue relaxation. In GTN-
`tolerant tissue, potency is reduced by 5- to 10-fold, but
`the potency of GTN still exceeds that of other nitrate
`
`Fig. 5. Effect of in vivo GTN tolerance, 1.0 mM propionaldehyde
`(PRO), or both on GTN-induced relaxation of isolated rat aorta. The
`EC50 values for GTN-induced relaxation were Control, 19.1 F 8.3 nM;
`Tolerant, 81.4 F 57 nM; Control + PRO, 0.42 F 0.06 AM; Tolerant +
`PRO, 2.2 F 1.5 AM. Each value represents the mean F SEM (n = 3 or
`4). All EC50 values were significantly different from each other ( p b
`.001, one-way ANOVA). Arrows represent fold-shifts on treatment with
`propionaldehyde in naive and tolerant tissues.
`
`vasodilators, such as ISDN, in nontolerant tissue. It is
`therefore tempting to envision multiple biotransformation
`pathways, with GTN utilizing a high-potency or high-
`affinity pathway, sensitive to tolerance, in addition to the
`low-affinity pathway open to all other nitrates. Biphasic
`concentration–response curves have been reported for
`GTN-induced relaxation and these have supported a
`dual-mechanism hypothesis for GTN, with high-affinity
`and low-affinity components [117–119]. It is perplexing
`that erithrityl tetranitrate, which incorporates the GTN
`moiety in its structure, is reported to be 10-fold less
`potent, to manifest no biphasic activity; and to abolish
`the putative high-affinity pathway for GTN [120].
`If (a) attenuated mechanism-based biotransformation
`is responsible for nitrate tolerance and (b) nitrate activity
`is mediated through NO release, the enzyme or agent
`responsible for this biotransformation must be able to
`mediate chemical reduction of nitrates to NO.
`
`NITRATES AS NITRIC OXIDE DONORS
`
`Detection and quantification of NO in complex
`biological systems and under physiological conditions
`remain challenging. A variety of methods are used for
`detecting NO, for example: quantification of cGMP;
`chemiluminescence detection;
`fluorescence detection
`using 4,5-diaminofluorescein; conversion of Fe(II)-
`oxyHb to metHb; spin trap/ESR detection (using, e.g.,
`Fe-diethylthiocarbamate (Fe(DETC)2), Fe(II)Hb,
`Fe(II)Mb, 2-phenyl-4,4,5,5-tetramethylimidazoline-1-
`oxyl-3-oxide); electrochemical detection (amperometric
`NO-specific and porphyrinic electrodes); Griess assay of
`
`Page 7 of 22
`
`

`

`Nitrates and NO release
`
`1129
`
`); and immunoassays usingNO2, NO3, or (NO2 + NO3
`
`
`
`
`anti-nitrotyrosine antibodies. Many of these methods are
`indirect and have been queried, for example, because of
`lack of specificity for NO and interference from other
`components of biological systems [121–125].
`The release of NO from nitrates in complex biological
`systems can often be observed using a variety of different
`methods, for example, exhaled NO levels were observed
`to be increased after high-dose i.v. bolus administration of
`GTN to coronary artery bypass patients [126]. In human
`plasma, NO release was observ

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket